This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scheinman, M. M. Articles by Abbott, J. A. Search for Related Content PubMed PubMed Citation Articles by Scheinman, M. M. Articles by Abbott, J. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ATROPINE Medline Plus Health Information Heart Attack

Circulation, Vol 52, 627-633, Copyright © 1975 by American Heart Association

ARTICLES

Use of atropine in patients with acute myocardial infarction and sinus bradycardia

MM Scheinman, D Thorburn and JA Abbott

Fifty-six patients with acute myocardial infarction complicated by sinus bradycardia (SB) were treated with intravenous atropine and monitored in a coronary care unit. Atropine decreased or completely abolished premature ventricular contractions (PVCs) and/or bouts of accelerated idioventricular rhythm in 27 of 31 patients (87%) and brought systemic blood pressure up to normal in 15 of 17 patients (88%) with hypotension. In addition, atropine administration was associated with improved atrioventricular conduction in 11 of 13 patients (85%) with acute inferior myocardial infarction associated with 2 degrees or 3 degrees atrioventricular block. Seven patients developed ten significant adverse effects: ventricular tachycardia or fibrillation in three, sustainedsinus tachycardia in three, increased PVCs in three, and toxic psychosis in one. These major adverse effects correlated with either a higher initial dose of atropine (i.e., 1.0 mg aa compared with the usual 0.5 or 0.6 mg) or a total cumulative dose exceeding 2.5 mg over 21/2 hours. Atropine is the drug of choice for management of patients with SB and hypotension and is effective in the treatment of ventricular arrhythmias as well as conduction disturbances in patients with inferior myocardial infarction. Serious adverse effects, however, preclude use of atropine without careful medical supervision.

This article has been cited by other articles:

				Adult Advanced Cardiac Life Support JAMA, October 28, 1992; 268(16): 2199 - 2241. [Abstract] [PDF]

				Standards and Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiac Care (ECC) JAMA, June 6, 1986; 255(21): 2905 - 2984. [Abstract] [PDF]

				Cardiovascular Disease: An Annotated Bibliography of Recent Literature: References to Journal Articles and Other Papers Ann Intern Med, October 1, 1976; 85(4): 544 - 548. [Abstract] [PDF]